Interpreting projected gastrointestinal cancer burden in Africa: The case of liver cancer

We read with great interest the article by Danpanichkul and colleagues reporting updated global estimates and projections for gastrointestinal cancer incidence and mortality through 2050 based on data from the GLOBOCAN 2022 database.1 The authors should be congratulated for providing a comprehensive and timely assessment that highlights the magnitude of the future gastrointestinal cancer burden and the pronounced regional and socioeconomic disparities that are expected to emerge. Of particular importance is their finding that Africa is projected to experience the largest relative increases in both incidence and mortality, which accentuates the urgent need for region-specific cancer control strategies. Within this broader gastrointestinal cancer framework, liver cancer warrants special attention in sub-Saharan Africa, where it remains a leading cause of cancer-related death and a major contributor to the region’s gastrointestinal cancer burden. Although the projections presented by Danpanichkul et al.1 appropriately emphasize Africa as a high-growth region, liver cancer trends in sub-Saharan Africa exhibit a distinctive and potentially misleading pattern that merits further discussion. Specifically, declining age-standardized incidence and mortality rates coexist with rapidly rising absolute numbers of cases and deaths: This is a paradox that has important implications for health system planning and policy interpretation.2 Using longitudinal Global Burden of Disease estimates and forward projections through 2050, our analyses of liver cancer in sub-Saharan Africa demonstrate that age-standardized rates are projected to gradually decline over the coming decades. However, these favorable rate trends mask a substantial and sustained increase in the absolute burden of liver cancer. Population growth and demographic aging are the dominant drivers of this divergence and are resulting in a marked expansion in the total number of individuals affected despite improvements in age-adjusted risk. Consequently, liver cancer will continue to exert growing pressure on already constrained health systems across the region, even in the absence of worsening age-specific risks. This dynamic closely aligns with, and further contextualizes, the findings of Danpanichkul et al., who report the steepest proportional increases in gastrointestinal cancer incidence and mortality in Africa overall.1 Liver cancer exemplifies how demographic forces can amplify the cancer burden in low- and middle-income settings, particularly when prevention and early-detection infrastructure remains limited. In sub-Saharan Africa, persistent exposure to viral hepatitis, incomplete coverage of hepatitis B birth-dose vaccination, limited access to antiviral therapy, and rising contributions from metabolic and alcohol-related liver disease collectively sustain a high baseline risk. When coupled with rapid population expansion, these factors translate into accelerating absolute case counts even as age-standardized rates decline. The policy implications of this paradox are substantial. Reliance on age-standardized trends alone may inadvertently convey a sense of progress that is not reflected in real-world service needs. Health systems must prepare for increasing demand for diagnostic, therapeutic, and palliative liver cancer services alongside continued investment in primary prevention. Expanded hepatitis B vaccination, scale-up of hepatitis B and C testing and treatment, integration of metabolic risk management into primary care, and strengthening of cancer surveillance and registry systems are all essential to mitigate the projected rise in absolute burden. Importantly, these interventions must be tailored to regional realities in sub-Saharan Africa, where underdiagnosis and incomplete cancer registration likely result in underestimation of the true burden.3 In conclusion, the work by Danpanichkul and colleagues1 provides a critical global benchmark for understanding future gastrointestinal cancer trends. Complementary, disease-specific analyses from sub-Saharan Africa highlight how liver cancer will continue to expand in absolute terms despite declining age-standardized rates, and they reinforce the urgency of targeted prevention and health system strengthening in the region. Together, these perspectives underline the fact that without sustained and regionally adapted interventions, the projected growth in gastrointestinal cancers, particularly liver cancer in sub-Saharan Africa, will pose a major challenge to global cancer control efforts in the coming decades. The authors declare no conflict of interest.